Improving Healthspan and Increasing Lifespan

Eos SENOLYTIX, Perseus SENOLYTIX, and Phoenix SENOLYTIX are affiliated with SENOTHERAPEUTIX, Inc., d/b/a GEROTHERAPEUTIX, Inc.

Aging is the primary risk factor for chronic diseases, including cancer, Alzheimer’s Disease, diabetes, osteoarthritis, macular degeneration, and sarcopenia along with many others.  Gerotherapeutics aim to target aging’s underlying biological processes to extend healthspan and reduce healthcare burdens.  It has been said that a successful gerotherapeutic would have a value that is too high to calculate — it instantly would become the most valuable medical intervention in history because of the number of person-years of healthy life that could be manufactured.

In 2017, SENOTHERAPEUTIX, Inc. was founded in Houston, TX focused on developing gerotherapeutics to improve healthspan and increase lifespan.  The Company’s dramatic discoveries and innovative technologies in the fields of geroscience and longevity medicine have been spun out into three wholly owned subsidiaries of SENOTHERAPEUTIX, Inc., which was registered in Texas as d/b/a GEROTHERAPEUTIX, Inc. in 2025: (1) Eos SENOLYTIX, a longevity company developing novel MitoXcel™ geropeptide therapeutics to improve healthspan and increase lifespan (2) Perseus SENOLYTIX, an oncology company developing novel MitoXcel™ oncopeptides to target cancer via this same novel mechanism as a potentially safe and effective new class of cancer therapeutics and (3) Phoenix SENOLYTIX, developing novel, controllable gene therapies utilizing our proprietary ApoptiCIDe™ purposeful cell elimination technology to improve healthspan and increase lifespan.  Visit our affiliate Companies to learn more about them, and our MitoXcel™ Technology website, that explains  the remarkable technology driving them!